Magdent
Magdent is leading innovation in dental implantology, leveraging FDA approved PEMF, reducing recovery time by X3, and treating #1 pain in implantology - peri implantitis.
Company Overview
Snapshot
Founded in May 2010 by Shlomo Barak and Moshe Neuman, Magdent operates with 11–50 employees. The company has raised $6.7 million across six funding rounds from three investors. In October 2022, Magdent secured funding from Catapult Education.
Business overview
Magdent is revolutionizing dental implantology through its innovative pulsed electromagnetic field (PEMF) healing abutments. The company's patented miniaturized electromagnetic devices (MEDs) integrate with standard implants to activate and accelerate the body’s natural biological healing processes. This technology is designed to reduce inflammation, suppress peri-implantitis (a common cause of implant failure), stimulate bone formation, and improve the quality of hard and soft tissue. Magdent's solutions aim to shorten recovery times by up to two-thirds and improve patient outcomes, particularly for high-risk individuals, serving the dental and medical device sectors within the Health Tech & Life Sciences industry.
Strategic signal
Magdent's technology, which uses electromagnetics to accelerate bone formation and osseointegration, was highlighted in March 2015. This indicates the company's early focus on leveraging advanced biophysical principles to address critical challenges in dental implant success and patient recovery, signaling a commitment to scientific validation and innovation in the field.
Company Intelligence Q&A
- What is Magdent's core technology?
- Magdent utilizes patented pulsed electromagnetic field (PEMF) healing abutments that work with standard dental implants to accelerate bone formation and osseointegration, reducing inflammation and improving tissue quality.
- When was Magdent founded and by whom?
- Magdent was founded in May 2010 by Shlomo Barak and Moshe Neuman.
- How much capital has Magdent raised to date?
- Magdent has raised a total of $6.7 million across six funding rounds.
- What is the primary problem Magdent's technology addresses in dental implantology?
- Magdent's technology primarily addresses peri-implantitis, a condition affecting approximately 40% of implant procedures, by promoting bone growth and reducing inflammation to prevent implant failure.